Clopidogrel injunction retained
Executive Summary
A preliminary injunction halting sales of generic Plavix by Apotex has been upheld by Washington, D.C. Federal Appeals Court, Sanofi-Aventis and Bristol-Myers Squibb announce Dec. 8. The ruling affirms the Aug. 31 decision by the U.S. District Court for the Southern District of New York granting Sanofi/Bristol's motion for a preliminary injunction enjoining Apotex from infringing Sanofi's patent by selling generic clopidogrel (1"The Pink Sheet" Sept. 4, 2006, p. 3). Sanofi/Bristol filed the motion for preliminary injunction Aug. 15 in response to Apotex' Aug. 8 "at risk" launch. Apotex said it is considering further review of the lower court decision. The trial on the underlying patent infringement dispute is scheduled to begin Jan. 22...
You may also be interested in...
Plavix Generic Blocked By Court, But Damage Lingers For Bristol And Sanofi
The impact of the launch of a generic version of Plavix - the second best selling drug in the world - will continue to weigh on Sanofi-Aventis and Bristol-Myers Squibb at least through the remainder of the year and possibly beyond despite a ruling in their favor barring Apotex' sale of generic clopidogrel
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: